investing – Cytonics Corporation

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

Science Corner, Investor Relations, Our StoryJanuary 6, 2026626Views 0Likes 0Comments

You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

#60 👎 Where Big Pharma Tried And Failed

Science CornerNovember 4, 2025645Views 0Likes 0Comments

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#59 🧬 Why is A2M being called a physiological guardian?

UncategorizedOctober 21, 2025661Views 0Likes 0Comments

Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

Investor RelationsOctober 14, 2025427Views 0Likes 0Comments

How Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement. It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then, our team has been hard…

#57: 👎 Why Cytonics Turned Down VC

Investor Relations, Our StoryAugust 27, 2025650Views 0Likes 0Comments

Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.

#56 🚗 Our CEO Delivers A Quick Message From the Road!

Investor Relations, Joey BoseAugust 16, 2025653Views 0Likes 0Comments

The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment.

#55 🧬 Perfecting Nature’s Blueprint

Science CornerJuly 1, 2025403Views 0Likes 0Comments

Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.

#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape

Investor RelationsJune 9, 20251KViews 0Likes 0Comments

Cytonics aims to address osteoarthritis, impacting over 500 million globally, with its innovative CYT-108 therapy. Positioned strategically in capital markets, the company targets Phase 2-ready investments. With strong intellectual property and funding strategies, Cytonics is well-prepared for M&A opportunities, benefiting from current biotech trends and investor interests.

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

Investor Relations, Our Story, Joey BoseMay 27, 2025675Views 0Likes 0Comments

Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.

#49 🦈 When a Shark Asks the Right Questions

Investor Relations, Our StoryMay 14, 2025851Views 0Likes 0Comments

Cytonics CEO Joey Bose discussed their groundbreaking approach to osteoarthritis with investor Kevin O’Leary. The biotech firm has treated over 10,000 patients and developed a therapy, CYT-108, which has completed Phase 1 trials. With $15M raised from 6,000 everyday investors, Cytonics challenges traditional Big Pharma funding models.

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

Investor Relations, Our StoryMarch 31, 20251KViews 0Likes 0Comments

Cytonics has completed its first-in-human trial for CYT-108, a recombinant protease inhibitor for knee osteoarthritis. The 22-patient Phase 1 study focused on safety and efficacy, providing data for an FDA IND application and Phase 2 protocol. This milestone boosts prospects for a disease-modifying therapy and enhances shareholder value.

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Investor Relations, Our StoryMarch 25, 2025649Views 0Likes 0Comments

Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

#60 👎 Where Big Pharma Tried And Failed

#59 🧬 Why is A2M being called a physiological guardian?

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

#57: 👎 Why Cytonics Turned Down VC

#56 🚗 Our CEO Delivers A Quick Message From the Road!

#55 🧬 Perfecting Nature’s Blueprint

#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

#49 🦈 When a Shark Asks the Right Questions

#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated